Creating new HIV vaccines using targeted nanoparticles
Official title: Development and characterization of germline-targeted nanoparticle immunogens toward a novel HIV Env epitope
Funded at Stanford University · NIH-11013783 · Data updated 2026-11-12
This study is exploring a new way to create vaccines for HIV by using tiny particles to help your immune system make powerful antibodies that can fight the virus, with the hope of improving prevention and treatment options for people living with HIV.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | January 16, 2024 |
| Project end | January 15, 2027 |
| Funding year | 2025 |
| Award (this year) | $44,862 |
| NIH project number | 5F30AI176917-02 |
| Project ID | NIH-11013783 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk of HIV infection or those living with HIV who may benefit from new preventive strategies.
✕Less likely to help
Patients who are already effectively managing their HIV with existing treatments may not see direct benefits from this research.
What this research studies
This research focuses on developing innovative vaccines for HIV by targeting a specific part of the virus known as the 'silent face' of gp120. The approach involves using nanoparticles to elicit broadly-neutralizing antibodies (bnAbs) from the immune system, which could potentially prevent HIV infection. By studying how these antibodies can be produced from different genetic backgrounds, the research aims to create a more effective vaccine strategy. Patients may benefit from advancements in HIV prevention and treatment through this novel approach.
Why it matters
Potential benefit: If successful, this research could lead to a more effective HIV vaccine that significantly reduces the risk of infection.
How similar studies have gone: Previous research has shown promise in developing vaccines targeting similar viral epitopes, indicating potential for success in this novel approach.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Carter, Josh — Stanford University
- Study coordinator: Carter, Josh
Related research
Other NIH-funded projects on the same topics.
-
Multimodal AI to predict CAR-T patient response and guide safer, smarter cell design
A Stanford team is building AI tools that use patient and CAR-T cell data to predict how well a CAR-T therapy will work and what design changes might boost effectiveness and safety for people with cancer.
-
Community-driven model to reduce overdose deaths through smarter resource use
A Stanford-led project uses a data-driven model to help counties pick the best ways to prevent opioid and stimulant overdoses and save lives.
-
Center for Dissemination and Implementation at Stanford: Research Core
A Stanford-based program is advancing how evidence-based addiction treatments are implemented across settings to help people with substance use disorders receive better care.
-
Center for Dissemination and Implementation At Stanford (C-DIAS)
A center-based program at Stanford aims to speed people who need addiction treatments to get evidence-based care.
-
Mitochondrial structure and neuron health in Alzheimer's and ALS
This grant studies how mitochondrial cristae structure in neurons is controlled and how its disruption may contribute to diseases like Alzheimer's and ALS.
-
Pediatric EMS seizures: simpler age-based midazolam dosing
A nationwide trial at EMS agencies tests whether using fixed, age-based dosing of midazolam for seizures in children improves treatment speed and safety.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.